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Abstract: Glioblastoma multiforme (G.B.M.) represents one of the commonest 
intracranial tumor associated with very poor prognosis. Despite recent advances in 
genomics and microneurosurgical techniques, chemotherapy regimens, radiation 
technology but despite of these mortality and morbidity still remains unacceptable very 
high. Various markers are utilized to stratify into different category in a desperate 
attempt to find out suitable therapeutic regimen to promote improved neurological 
outcome. Authors briefly reviews various biomarkers and utility in management of GBM 
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Introduction 
Glioblastoma multiforme originates from 
astrocytes.1-5 The different types are markers 
are expressed differently in different types and 
molecular subtypes of GBM.6-14 However, with 
the emergence of new molecular biomarkers 
and its regulation such as epidermal growth 
factor receptor vIII, O6-methylguanine-DNA 
methyltransferase, Isocitrate dehydrogenase 
mutation.1-6 Further, glioblastoma specific 
microRNAs like miR-10b and miR-21 is 
labelled as promising prognostic values.  
As GBM represent highly malignant 
potential is associated with widespread genetic 
alterations and protein expression, which is 
utilize to categorize into various types and may 
have prognostic significance.  
Various molecular biomarkers of 
Glioblastoma multiforme includes:  
1. O6-methylguanine-DNA methyltransferase 
(MGMT): It is located on the chromosome 
number 10q26, the MGMT gene encodes 
proteins, which are consumed in DNA repair. 
The methylation of this gene increases the 
efficacy of an alkylating agent like 
temozolamide after chemoradiotherapy.  
2. Epidermal growth factor receptor 
(EGFR): Amplification of Epidermal growth 
factor receptor and the genetic rearrangement 
of EGFR (EGFRvIII) are considered as 
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common hallmarks of GBM. GBM has highly 
proliferative nature controlled by the presence 
of key growth factors and receptors; it can 
activate pathways essential for GBM tumor 
cells to proliferate and its activation causes 
decreased integrity of G1 to S checkpoint in 
the cell cycle, leading to excessive 
proliferation. Often presenting itself in 
patients with amplified wild-type EGFR, 
patients with EGFRvIII mutation have 
significantly lower survival as compared to 
those without the mutation (1.4 years).2 
3. Platelet-derived growth factor alpha 
receptor: It represents a receptor for specific 
growth factors whose over expression would 
lead to abnormal and uncontrolled cellular 
growth. In, GBM may have either A or B 
types.3 
4. Isocitrate dehydrogenase: is a protein 
enzyme coded by genes in chromosome 
number 2, whose primary function is catalyze 
the oxidative decarboxylation process within 
the Krebs cycle.3 
5. Tumor protein 53: It codes for a widely 
known tumor suppressor protein, p53. It 
serves various roles in suppressing 
tumorigenesis. It is observed at a much higher 
rate in secondary GBM (90%) compared to 
cases in primary GBM (30%), and may even 
remain absent in few primary GBM.4. 5 
II. MICRORNA as biomarkers (MiRNA): 
These short RNA non-coding molecules 
which are often correlated with progression 
and proliferation of GBM cells. The micron 
plays a major role in the development and 
progression of tumor based on its pathway 
modulatory abilities in oncogenic and tumor 
suppressor genes. The utilization of miRNA as 
molecular biomarkers is being reported to 
yield >90% specificity in detection of GBM 
itself MiRNA is thought to be an useful 
biomarker in oncology for cancer detection 
due to its less-invasive approach, mainly from 
samples collected from various body fluid and 
it also allows patient stratification over the 
usual prognostications.6,7  
1. miR-21: It is expressed in GBM as well as 
malignancy of ovary, cervix and lungs. 
Modulatory ability of miR-21 lead to affect 
tumor suppressor genes such as PTEN, RECK, 
FasL and PDCD4.8,9 It is up regulated in GBM 
source sample is CSF, blood and urine. It is 
considered as prognostic marker  
2. miR-10b: It is considered as prognostic 
and predictive marker of GBM. Source sample 
is CSF, blood and urine. It is considered as 
prognostic marker  
3. miR-15b: These are is down regulated in 
GBM, and also represents as one of the 
prognostic and predictive marker.  
4. miR-137: these are usually down 
regulated in GBM and presents another 
predictive and prognostic GBM marker.10, 11 
The molecular biomarkers and micro RNA 
biomarker were originally were designed and 
routinely utilized as drug targets to develop 
recent updared therapies. Authors strongly 
hope biomarker development and advances in 
therapy in near future may protect humanity 
against atrocities of the GBM.12-14  
Conclusion 
The aggressiveness nurture of GBM, 
dictate the urgent need of development of 
biomarkers for accurate and early diagnosis 
and to precisely categorization for 
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responsiveness to various therapeutic 
chemotherapy and other supportive regimen.  
The molecular biomarkers and micro RNA 
biomarker were utilized as drug targets to 
develop therapies. Authors strongly hope 
biomarker development and advances in 
therapy in near future may protect humanity 
against atrocities of the GBM.  
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